Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients. Recent work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics for the development of a cell-based therapy for diabetes. Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. Semma Therapeutics is working to bring this new therapeutic option to the clinic and improve the lives of patients with diabetes.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
03/24/15	$44,000,000	Series A	ARCH Venture Partners Medtronic MPM Capital	undisclosed
11/30/17	$114,000,000	Series B	6 Dimensions Capital ARCH Venture Partners Cowen Investments Eight Road Ventures F-Prime Capital Partners JDRF T1D Fund Medtronic MPM Capital Novartis ORI Healthcare Fund SinoPharm Capital Wu Capital	undisclosed